Talampanel

Talampanel epilepsi,^[1]^[2] malign gliomalar,^[3] ve amyotrofik lateral skleroz (ALS) tedavisi için araştırılmış bir ilaçtır.^[4]

Mayıs 2010 itibarıyla, ALS denemesinin sonuçları olumsuz bulunmuştur.^[5] Talampanel şu anda geliştirme aşamasında değildir.

Talampanel, merkezi sinir sisteminde bir tür iyonotropik glutamat reseptörü olan AMPA reseptörünün rekabetçi olmayan bir antagonisti olarak işlev görür.^[6]

Klinik çalışmalarda epilepsi için etkinlik göstermiştir, ancak zayıf farmakokinetik profili, yani günde birden fazla doz gerektiren kısa bir terminal yarılanma ömrü (3 saat) nedeniyle gelişimi askıya alınmıştır.^[7]

Kaynakça[değiştir | kaynağı değiştir]

^ Luszczki (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions". Pharmacological Reports. 61 (2): 197-216. doi:10.1016/s1734-1140(09)70024-6. PMID 19443931.
^ Bialer (2007). "Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII)". Epilepsy Research. 73 (1): 1-52. doi:10.1016/j.eplepsyres.2006.10.008. PMID 17158031.
^ Iwamoto (2010). "Phase II Trial of Talampanel, a Glutamate Receptor Inhibitor, for Adults with Recurrent Malignant Gliomas". Cancer. 116 (7): 1776-1782. doi:10.1002/cncr.24957. PMC 2846997 $2. PMID 20143438.
^ Pascuzzi (2009). "A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis. 11 (3): 266-271. doi:10.3109/17482960903307805. PMID 19961264.
^ Talampanel Trial 23 Mart 2011 tarihinde Wayback Machine sitesinde arşivlendi., Talampanel Trial on alsa.org
^ Aujla (2009). "Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model". Epilepsia. 50 (4): 694-701. doi:10.1111/j.1528-1167.2008.01947.x. PMC 2672962 $2. PMID 19220413.
^ "AMPA Receptors as Therapeutic Targets for Neurological Disorders". Adv Protein Chem Struct Biol. Advances in Protein Chemistry and Structural Biology. 103: 203-61. 2016. doi:10.1016/bs.apcsb.2015.10.004. ISBN 9780128047941. PMID 26920691.

[1] Luszczki (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions". Pharmacological Reports. 61 (2): 197-216. doi:10.1016/s1734-1140(09)70024-6. PMID 19443931.

[2] Bialer (2007). "Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII)". Epilepsy Research. 73 (1): 1-52. doi:10.1016/j.eplepsyres.2006.10.008. PMID 17158031.

[3] Iwamoto (2010). "Phase II Trial of Talampanel, a Glutamate Receptor Inhibitor, for Adults with Recurrent Malignant Gliomas". Cancer. 116 (7): 1776-1782. doi:10.1002/cncr.24957. PMC 2846997 $2. PMID 20143438.

[4] Pascuzzi (2009). "A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis. 11 (3): 266-271. doi:10.3109/17482960903307805. PMID 19961264.

[5] Talampanel Trial 23 Mart 2011 tarihinde Wayback Machine sitesinde arşivlendi., Talampanel Trial on alsa.org

[6] Aujla (2009). "Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model". Epilepsia. 50 (4): 694-701. doi:10.1111/j.1528-1167.2008.01947.x. PMC 2672962 $2. PMID 19220413.

[pmid26920691-7] "AMPA Receptors as Therapeutic Targets for Neurological Disorders". Adv Protein Chem Struct Biol. Advances in Protein Chemistry and Structural Biology. 103: 203-61. 2016. doi:10.1016/bs.apcsb.2015.10.004. ISBN 9780128047941. PMID 26920691.

[1]

[2]

[3]

[4]

[5]

[6]

[7]